(Q52538397)

2 May 2018

title

Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. (English)

1 reference

2 May 2018

1 reference

1 reference

1 reference

1 reference

5

Neuwelt EA

1 reference

2 May 2018

author name string

Remsen LG

1

1 reference

2 May 2018

Trail PA

2

1 reference

2 May 2018

Hellström I

3

1 reference

2 May 2018

Hellström KE

4

1 reference

2 May 2018

language of work or name

English

0 references

publication date

1 March 2000

1 reference

2 May 2018

published in

Neurosurgery

1 reference

2 May 2018

volume

46

1 reference

2 May 2018

issue

3

1 reference

2 May 2018

page(s)

704-709

1 reference

2 May 2018

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results

cites work

1 reference

https://api.crossref.org/works/10.1097%2F00006123-200003000-00034

Anti-tumor antibody BR96 blocks cell migration and binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00006123-200003000-00034

The next frontier of molecular medicine: delivery of therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00006123-200003000-00034

Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00006123-200003000-00034

Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00006123-200003000-00034

10.1097/00006123-200003000-00034

21 January 2018

Identifiers

DOI

1 reference

2 May 2018

PubMed ID

10719867

1 reference

2 May 2018